RecruitingPhase 1NCT07054684
Study of BHV-1400 in IgA Nephropathy
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
Sponsor
Biohaven Therapeutics Ltd.
Enrollment
20 participants
Start Date
Jul 30, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria1
- \. Participants must have biopsy-confirmed IgA Nephropathy
Exclusion Criteria2
- Any secondary IgAN
- Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
Interventions
DRUGBHV-1400
BHV-1400 is delivered subcutaneously (SC)
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07054684
Related Trials
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
NCT0671240738 locations
Nefecon and Ambrisentan in IgA Nephropathy
NCT070308941 location
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
NCT0667638412 locations
TESTING -ON Post-Trial ObservatioNal Cohort Study
NCT0543432558 locations
National Registry of Rare Kidney Diseases
NCT060658521 location